The landmark ATHENA clinical study helped shape our understanding of the role of high-risk HPV testing in cervical cancer screening
Absolute risk of ≥CIN2 stratified by hrHPV status in the ATHENA NILM population3
Conclusion: Nearly 1 in 7 women with normal cytology who were HPV 16+ were shown to have CIN2+ that was missed by cytology.4
Request copies of the clinical research manuscripts.
Absolute risk of ≥CIN3 stratified by hrHPV status in the ATHENA NILM population3
Conclusion: Nearly 1 in 8 women with normal cytology who were HPV 16+ were shown to have CIN3+ that was missed by cytology.4
Conclusion: Almost all of the cases of ≥CIN3 missed by cytology were identified by the cobas® HPV Test.4
Conclusion: Women with normal cytology who are positive for HPV 16 and/or HPV 18, and women with ASC-US who are pooled hrHPV positive share a high and immediate risk of cervical precancer.3,8
Hear more from the experts on the implications of the ATHENA HPV trial.
1. The American College of Obstetricians and Gynecologists. ACOG Practice Bulletin. Clinical Management Guidelines for Obstetrician-Gynecologists: Screening for Cervical Cancer. November, 2012
2. Saslow D et al, Journal of Lower Genital Tract Disease, Volume 16, Number 3, 2012
3. Wright TC Jr, Stoler MH, Sharma A, Zhang G, Behrens CM, Wright TL. Evaluation of HPV-16 and HPV-18 genotyping for the triage of women with high-risk HPV+ cytology-negative results. Am J Clin Pathol. 2011;136:578-586.
4. cobas® 4800 HPV Test US package insert. April 2011.
5. Huh W, et al. 27th International Papillomavirus Conference, Berlin, Germany. Sept 17-22, 2011, OP-229.
6. Roche data on file. 2011.
7. American Society for Colposcopy and Cervical Pathology. HPV genotyping clinical update. http://www.asccp.org/Portals/9/docs/pdfs/Consensus Guidelines/clinical_update_20090408.pdf. Accessed August 9, 2011
8. Stoler MH, Wright TC, Sharma A, et al. High-risk human papillomavirus testing in women with ASC-US cytology: results from the ATHENA HPV study. Am J Clin Pathol. 2011;135(3):468-475.